BioSpace News Archive

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2022, after the market close on August 4, 2022.

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report second quarter 2022 financial results and provide a corporate update.

Applied Genetic Technologies Corporation announced that management will be participating in the following investor conferences.

Cytokinetics, Incorporated announced that on July 29, 2022 it granted stock options to purchase an aggregate of 88,200 shares of common stock to 11 new employees, whose employment commenced in July 2022, as a material inducement to their employment.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months of 2022 financial results on Monday, August 8, 2022 after the close of the U.S. financial markets.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development.

Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported second quarter 2022 financial results and business highlights.

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 4, 2022, after the close of the U.S. financial markets.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company approved the grant of stock options to purchase an aggregate of 26,100 shares of Karyopharm’s common stock and an aggregate of 18,000 restricted stock units to eight newly-hired employees.